Outcomes | No. of trials | No. of participants | WMD or OR (95% CI) | Subtotal p value | Subtotal Heterogenicity (I2 = %) | p value between subgroup (I2 = %) | p value | |
---|---|---|---|---|---|---|---|---|
Antiplatelet | Control | |||||||
In-hospital mortality | ||||||||
Aspirin | 3 | 11/456 | 24/1128 | 1.11 (0.54-2.32) | 0.77 | 0 | 0.81 | 0.59 |
Clopidogrel | 4 | 2/106 | 26/1242 | 1.17 (0.34-3.99) | 0.80 | 0 | ||
Clopidogrel and aspirin | 1 | 1/34 | 8/619 | 2.31 (0.28-19.05) | 0.44 | Not applicable | ||
30-day mortality | ||||||||
Aspirin | 2 | 25/371 | 42/756 | 1.22 (0.72-2.07) | 0.47 | 89 | 0.64 | 0.56 |
Clopidogrel | 5 | 8/182 | 121/2070 | 1.20 (0.55-2.60) | 0.65 | 0 | ||
Clopidogrel and aspirin | 1 | 1/34 | 39/619 | 0.45 (0.06-3.38) | 0.44 | Not applicable | ||
1-year mortality | ||||||||
Aspirin | 2 | 85/371 | 131/756 | 1.91 (0.56-6.54) | 0.30 | 90 | 0.55 | 0.43 |
Clopidogrel | 3 | 29/110 | 488/1534 | 0.90 (0.49-1.64) | 0.72 | 41 | ||
Clopidogrel and aspirin | 1 | 7/34 | 117/619 | 1.11 (0.47-2.62) | 0.81 | Not applicable | ||
Drop in hemoglobin | ||||||||
Aspirin | 4 | 450 | 879 | 0.12 (− 0.06-0.31) | 0.18 | 0 | 0.88 | 0.08 |
Clopidogrel | 6 | 201 | 1017 | 0.16 (− 0.10-0.42) | 0.22 | 0 | ||
Clopidogrel and aspirin | 1 | 34 | 619 | 0.00 (− 0.58-0.58) | 1.00 | Not applicable | ||
Number of patients receiving blood transfusion | ||||||||
Aspirin | 4 | 253/450 | 465/879 | 1.16 (0.91-1.46) | 0.23 | 0 | 0.39 | 0.03 |
Clopidogrel | 10 | 118/361 | 875/2965 | 1.19 (0.90-1.59) | 0.23 | 36 | ||
Clopidogrel and aspirin | 1 | 24/34 | 337/619 | 2.01 (0.94-4.27) | 0.07 | Not applicable | ||
Mean number of units of blood transfused | ||||||||
Aspirin | 5 | 530 | 1185 | 0.13 (− 0.13-0.40) | 0.32 | 49 | 0.23 | 0.07 |
Clopidogrel | 7 | 250 | 2487 | 0.15 (− 0.25-0.56) | 0.46 | 71 | ||
Clopidogrel and aspirin | 2 | 49 | 641 | 0.69 (0.10-1.28) | 0.02 | 0 | ||
Length of hospital stay | ||||||||
Aspirin | 2 | 380 | 808 | − 0.39 (− 0.83-0.06) | 0.09 | 0 | 0.03 | 0.76 |
Clopidogrel | 6 | 257 | 1203 | 0.58 (− 0.17-1.34) | 0.13 | 0 | ||
Clopidogrel and aspirin | 2 | 49 | 641 | 0.97 (− 0.40-2.34) | 0.17 | 0 | ||
Reoperation | ||||||||
Aspirin | 2 | 3/223 | 3/304 | 1.35 (0.28-6.61) | 0.71 | 0 | 0.93 | 0.29 |
Clopidogrel | 6 | 10/216 | 33/1037 | 1.47 (0.70-3.09) | 0.31 | 0 | ||
Acute coronary syndrome | ||||||||
Aspirin | 1 | 8/118 | 5/137 | 1.92 (0.61-6.04) | 0.26 | Not applicable | 0.52 | 0.004 |
Clopidogrel | 6 | 14/240 | 19/984 | 2.27 (1.07-4.81) | 0.03 | 0 | ||
Clopidogrel and aspirin | 1 | 3/15 | 0/22 | 12.60 (0.60-264.14) | 0.10 | Not applicable | ||
Cerebrovascular events | ||||||||
Aspirin | 2 | 2/140 | 1/159 | 1.64 (0.27-9.79) | 0.59 | 39 | 0.76 | 0.53 |
Clopidogrel | 3 | 2/84 | 4/249 | 1.77 (0.35-9.04) | 0.49 | 0 | ||
Clopidogrel and aspirin | 1 | 0/15 | 1/22 | 0.46 (0.02-12.12) | 0.64 | Not applicable | ||
Deep venous thrombosis | ||||||||
Aspirin | 3 | 9/476 | 11/923 | 1.50 (0.58-3.84) | 0.40 | 61 | 0.94 | 0.30 |
Clopidogrel | 4 | 2/162 | 14/1435 | 1.60 (0.45-5.74) | 0.47 | 0 | ||
Clopidogrel and aspirin | 1 | 0/34 | 9/619 | 0.93 (0.05-16.33) | 0.96 | Not applicable | ||
Pulmonary embolism | ||||||||
Aspirin | 2 | 2/358 | 4/786 | 1.06 (0.22-5.14) | 0.95 | 0 | 0.79 | 0.54 |
Clopidogrel | 6 | 2/251 | 14/1664 | 1.37 (0.44-4.23) | 0.59 | 0 | ||
Clopidogrel and aspirin | 1 | 0/34 | 2/619 | 3.58 (0.17-76.02) | 0.41 | Not applicable | ||
Wound-related complications | ||||||||
Aspirin | 4 | 14/498 | 25/945 | 0.86 (0.44-1.69) | 0.67 | 0 | 0.34 | 0.48 |
Clopidogrel | 8 | 14/287 | 35/2398 | 1.52 (0.75-3.09) | 0.24 | 0 | ||
Clopidogrel and aspirin | 2 | 2/49 | 10/641 | 2.60 (0.49-13.74) | 0.26 | 0 | ||
Major bleeding | ||||||||
Aspirin | 1 | 3/98 | 10/342 | 1.05 (0.28-3.89) | 0.94 | Not applicable | 0.58 | 0.48 |
Clopidogrel | 3 | 5/91 | 13/444 | 1.75 (0.52-5.91) | 0.37 | 0 |